Markets:

Overview

News

Currencies

International

Treasuries

Soleno Therapeutics, Inc. - Common Stock (NQ:SLNO)

47.71 +0.06 (+0.13%)

Streaming Delayed Price Updated: 2:28 PM EST, Dec 29, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Soleno Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗

December 03, 2025

Soleno just turned profitable for the first time—right as a major fund made its move.

Via The Motley Fool

Topics Regulatory Compliance

Bragar Eagel & Squire, P.C. Encourages Agilon, Soleno, Avita, and Coty Investors to Contact the Firm Regarding Ongoing Investigations

December 03, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Bragar Eagel & Squire, P.C. Encourages Agilon, Soleno, Avita, and Coty Investors to Contact the Firm Regarding Ongoing Investigations

November 18, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

Earnings Scheduled For November 4, 2025 ↗

November 04, 2025

Via Benzinga

Soleno Therapeutics Unveils $100 Million Buyback Citing 'Underappreciated' Future ↗

November 11, 2025

Soleno Therapeutics (SLNO) approved $100M share repurchase program & entered ASR agreement with Jefferies LLC to buy back its stock.

Via Benzinga

PubMatic Posts Upbeat Q3 Results, Joins Energy Vault, RealReal And Other Big Stocks Moving Higher On Tuesday ↗

November 11, 2025

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 11, 2025

Via Benzinga

SLNO INVESTIGATION ALERT: Robbins Geller Rudman & Dowd LLP Launches Investigation into Soleno Therapeutics, Inc., and Encourages Investors and Potential Witnesses to Contact Law Firm

November 11, 2025

From Robbins Geller Rudman & Dowd LLP

Via Business Wire

Bragar Eagel & Squire, P.C. Is Investigating Agilon, Soleno, Avita, and Coty and Encourages Investors to Contact the Firm

November 10, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

These stocks are moving in today's session ↗

November 05, 2025

Curious about what's happening in today's session? Check out the latest stock movements and price changes.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

November 05, 2025

Via Benzinga

Wednesday's session: gap up and gap down stocks ↗

November 05, 2025

Let's have a look at what is happening on the US markets on Wednesday. Below you can find the gap up and gap down stocks in today's session.

Via Chartmill

Super Micro Computer Posts Downbeat Q1 Results, Joins Pinterest, Axon Enterprise And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

November 05, 2025

Via Benzinga

These stocks that are showing activity before the opening bell on Wednesday. ↗

November 05, 2025

The US market is yet to commence its session on Wednesday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements.

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

November 05, 2025

Via Benzinga

Why Teradata Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket ↗

November 05, 2025

Via Benzinga

What's going on in today's after hours session ↗

November 04, 2025

Let's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's After-Market Session ↗

November 04, 2025

Via Benzinga

Rosen Law Firm Encourages Soleno Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation – SLNO

October 30, 2025

From The Rosen Law Firm, P.A.

Via Business Wire

SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

October 27, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

October 20, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

October 15, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

October 12, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

SOLENO (SLNO) REMINDER: Bragar Eagel & Squire, P.C. Reminds Investors of the Investigation into Soleno Therapeutics, Inc. and Encourages Investors to Contact the Firm

October 09, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

October 08, 2025

Via Benzinga

SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

October 02, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

SLNO Investor News: If You Have Suffered Losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

September 29, 2025

From The Rosen Law Firm PA

Via GlobeNewswire

SOLENO INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigation into Therapeutics, Inc. on Behalf of Soleno Stockholders and Encourages Investors to Contact the Firm

September 25, 2025

From Bragar Eagel & Squire

Via GlobeNewswire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Soleno Therapeutics, Inc. - SLNO

September 24, 2025

From Pomerantz LLP

Via GlobeNewswire

Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short ↗

September 24, 2025

Acadia's Phase 3 Compass Prader-Willi syndrome trial failed to meet endpoints, but the company projects $1 billion in sales in 2025 and highlights a strong pipeline outlook.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.